These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3092723)

  • 81. Current status of posttransfusion hepatitis.
    Alter HJ; Holland PV; Purcell RH
    Pathobiol Annu; 1980; 10():135-56. PubMed ID: 6777742
    [No Abstract]   [Full Text] [Related]  

  • 82. Surveillance for posttransfusion hepatitis by a community hospital. Another view.
    Wenk RE; Brewer MK; Bass G; Bishop K
    Transfusion; 1981; 21(5):557-9. PubMed ID: 6794194
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Posttransfusion hepatitis in Toronto, Canada.
    Feinman SV; Berris B; Bojarski S
    Gastroenterology; 1988 Aug; 95(2):464-9. PubMed ID: 3134269
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Transfusion-associated or nosocomial hepatitis G virus infection in patients undergoing surgery.
    Lunel F; Frangeul L; Chuteau C; Fretz C; Thiers V; Azar N; Bidet JM; Huraux JM; Bréchot C; Valla D; Opolon P
    Transfusion; 1998; 38(11-12):1097-103. PubMed ID: 9838943
    [TBL] [Abstract][Full Text] [Related]  

  • 85. A donor implicated in two cases of post-transfusion non-A, non-B hepatitis.
    Barbara JA; Contreras M; Briggs M
    Vox Sang; 1983; 45(1):87-8. PubMed ID: 6410587
    [No Abstract]   [Full Text] [Related]  

  • 86. Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion-associated hepatitis: final report of a prospective trial.
    González A; Esteban JI; Madoz P; Viladomiu L; Genesca J; Muñiz E; Enríquez J; Torras X; Hernández JM; Quer J
    Hepatology; 1995 Aug; 22(2):439-45. PubMed ID: 7635410
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Post-transfusion non-A, non-B hepatitis after cardiac surgery. Prospective analysis of donor blood anti-HBc antibody as a predictive indicator of the occurrence of non-A, non-B hepatitis in recipients.
    Aymard JP; Janot G; Gayet S; Guillemin C; Canton P; Gaucher P; Streiff F
    Vox Sang; 1986; 51(3):236-8. PubMed ID: 3101289
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Analysis of guanase by agarose gel electrophoresis and activity staining.
    Nishikawa Y; Fukumoto K; Watanabe F
    Enzyme; 1985; 33(3):143-6. PubMed ID: 2414096
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Studies of donors who transmit posttransfusion hepatitis.
    Tabor E; Hoofnagle JH; Smallwood LA; Drucker JA; Pineda-Tamondong GC; Ni LY; Greenwalt TJ; Barker LF; Gerety RJ
    Transfusion; 1979; 19(6):725-31. PubMed ID: 230620
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Post-transfusion hepatitis in Australia. Report of the Australian Red Cross study.
    Cossart YE; Kirsch S; Ismay SL
    Lancet; 1982 Jan; 1(8265):208-13. PubMed ID: 6119566
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Purification of human liver guanase and characterization of antibody against it by immunoblotting.
    Ito S; Iwasaki A; Mizobuchi M; Matsuda Y
    Clin Biochem; 1990 Apr; 23(2):113-20. PubMed ID: 2372926
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Impacts of blood screening on the incidence of posttransfusion hepatitis C in Japan.
    Yoshizawa H; Watanabe J
    Curr Stud Hematol Blood Transfus; 1994; (61):182-94. PubMed ID: 7525155
    [No Abstract]   [Full Text] [Related]  

  • 93. Should donor blood be screened for elevated alanine aminotransferase levels? A cost-effectiveness analysis.
    Silverstein MD; Mulley AG; Dienstag JL
    JAMA; 1984 Nov 23-30; 252(20):2839-45. PubMed ID: 6436522
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Posttransfusion hepatitis in Spain. A prospective study.
    Hernández JM; Piqueras J; Carrera A; Triginer J
    Vox Sang; 1983; 44(4):231-7. PubMed ID: 6302997
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Histochemical and immunohistochemical investigation of guanase and nedasin in human tissues.
    Kubo K; Honda H; Honda H; Sannomiya K; Aying Y; Mei W; Mi S; Aoyagi E; Simizu I; Ii K; Ito S
    J Med Invest; 2006 Aug; 53(3-4):264-70. PubMed ID: 16953063
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study.
    Busch MP; Korelitz JJ; Kleinman SH; Lee SR; AuBuchon JP; Schreiber GB
    Transfusion; 1995; 35(11):903-10. PubMed ID: 8604486
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Reducing the incidence of non-A,non-B post-transfusion hepatitis by testing donor blood for alanine aminotransferase: economic considerations.
    Hornbrook MC; Dodd RY; Jacobs P; Friedman LI; Sherman KE
    N Engl J Med; 1982 Nov; 307(21):1315-21. PubMed ID: 6813736
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Anti-HBc testing in an effort to reduce the incidence of posttransfusion non-A, non-B hepatitis.
    Kline WE
    Beitr Infusionther Klin Ernahr; 1987; 18():6-12. PubMed ID: 3125834
    [No Abstract]   [Full Text] [Related]  

  • 99. Serum guanase activity in hepatitis C virus infection.
    Shaw T; Li J; Bowden DS; Cooksley G; Locarnini SA
    Adv Exp Med Biol; 1994; 370():475-82. PubMed ID: 7544951
    [No Abstract]   [Full Text] [Related]  

  • 100. [Determination of CSF guanase activity in multiple sclerosis: a comparative study on various parameters to monitor the disease activity].
    Kaneshige Y; Matsumoto H; Chiba S; Hashimoto S; Noro H
    Rinsho Shinkeigaku; 1989 Jul; 29(7):854-8. PubMed ID: 2805507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.